BIONET Therapeutics Corp. (7808.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$36.95 (-2.12%) as of
Key statistics
- Market cap
- 2.59B
- EPS (TTM)
- -1.20
- Dividend yield
- 0.00%
- 52-week range
- 28.55 – 64.50
- Revenue (TTM)
- 196.63M
- Profit margin
- -42.77%
- Volume
- 14.33k
About BIONET Therapeutics Corp.
BIONET Therapeutics Corp., a biopharmaceutical company, develops regenerative medicine cell preparations for acute and severe diseases. The company develops treatment for adult respiratory distress syndrome, pulmonary fibrosis, chronic kidney disease, acute wound healing, chronic wound healing of diabetic ulcers, osteoarthritis, and dry eye syndrome. It also provides mammalian and plant sourced exosomes, and CRDMO services. The company's pipeline includes BU-01 which is in Phase 2 trail for pulmonary fibrosis and ARDS; and is in phase 1 trials for chronic kidney diseases and chronic wound, as well as ExoTear that is in preclinical trial for the treatment of dry eye. The company was founded in 2022 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
- Employees
- 105
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.